On Monday, Capricor Therapeutics Inc (NASDAQ: CAPR) was 5.09% up from the session before settling in for the closing price of $11.78. A 52-week range for CAPR has been $3.52 – $23.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 85.83% over the past five years. When this article was written, the company’s average yearly earnings per share was at 96.52%. With a float of $40.15 million, this company’s outstanding shares have now reached $45.68 million.
Let’s look at the performance matrix of the company that is accounted for 160 employees. In terms of profitability, gross margin is 100.0%, operating margin of -329.9%, and the pretax margin is -317.13%.
Capricor Therapeutics Inc (CAPR) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Capricor Therapeutics Inc stocks. The insider ownership of Capricor Therapeutics Inc is 12.16%, while institutional ownership is 40.49%. The most recent insider transaction that took place on Sep 20 ’24, was worth 14,999,998. In this transaction 10% Owner of this company bought 2,798,507 shares at a rate of $5.36, taking the stock ownership to the 7,090,351 shares.
Capricor Therapeutics Inc (CAPR) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 96.52% per share during the next fiscal year.
Capricor Therapeutics Inc (NASDAQ: CAPR) Trading Performance Indicators
You can see what Capricor Therapeutics Inc (CAPR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.55. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 32.60.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.42, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -0.53 in one year’s time.
Technical Analysis of Capricor Therapeutics Inc (CAPR)
Capricor Therapeutics Inc (NASDAQ: CAPR) saw its 5-day average volume 2.24 million, a positive change from its year-to-date volume of 1.71 million. As of the previous 9 days, the stock’s Stochastic %D was 51.04%. Additionally, its Average True Range was 1.26.
During the past 100 days, Capricor Therapeutics Inc’s (CAPR) raw stochastic average was set at 59.93%, which indicates a significant increase from 52.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 114.73% in the past 14 days, which was lower than the 120.53% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.72, while its 200-day Moving Average is $13.28. Nevertheless, the first resistance level for the watch stands at $12.62 in the near term. At $12.85, the stock is likely to face the second major resistance level. The third major resistance level sits at $13.29. If the price goes on to break the first support level at $11.95, it is likely to go to the next support level at $11.51. Assuming the price breaks the second support level, the third support level stands at $11.28.
Capricor Therapeutics Inc (NASDAQ: CAPR) Key Stats
There are 45,677K outstanding shares of the company, which has a market capitalization of 565.86 million. As of now, sales total 22,270 K while income totals -40,470 K. Its latest quarter income was 11,130 K while its last quarter net income were -7,120 K.
